Investigational new drugGLP-1
Compound 61426
Formula Pending
Molecular Mass
N/A
CAS Registry
AUTO-061426
Risk Class
MODERATE
Last Audit
Feb 3, 2108
Research Abstract
GLP-1 candidate engineered for cognitive resilience initiatives with automated dossier coverage.
Compound 61426 is a glp-1 asset inside glp-1 innovation track initiatives, optimized for cognitive resilience and neuroprotection.
The dossier currently sits in investigational new drug with a moderate risk rating, meaning it is requires layered oversight with metabolic labs.
Supply records cite CAS AUTO-061426 with updates logged 2108-02-03.
Acquisition Protocol
Authorized research personnel may request deployment of this compound for laboratory analysis.
Primary Vectors
Cognitive resilienceNeuroprotection
Nomenclature
CX-61426GLP-1 Program 61426
Reference Material
- [1] Anubis Compound Registry • CAS AUTO-061426
- [2] Operations Pulse • GLP-1 innovation track
- [3] Risk Governance Ledger • MODERATE clearance for COMPOUND-61426